Blog

Calendar page October of the year 2025 white color in meeting room in office.

Major developments in European MedTech this week focused on regulatory turbulence and the industry's coordinated pressure for immediate reform of the EU's medical device laws. The central theme is the European Commission's "Call for Evidence" on the future of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). 1. Intense Pressure for MDR/IVDR Legislative Reform The key development is the industry's comprehensive and unified response to the European Commission's public consultation, with MedTech Europe leading the charge: Urgent Call for Structural Change: MedTech Europe, the industry's trade body, strongly advocated for a systematic and structural revision of both the MDR and IVDR. They assert that the current regulations have "structural problems" that are making regulatory processes slow, unpredictable, costly and complex, leading to a drain of innovation from Europe. Need for Centralised Governance: A major proposal from the industry is the creation of a single, accountable and dedicated governance structure at the EU level. This body would oversee the decentralised network of Notified Bodies (NBs), aiming to harmonise decisions and increase the efficiency of the CE-marking system. Bridging Measures Requested: The industry is pushing for immediate, short-term relief measures (bridging measures) to mitigate the current risks, including: Postponement of Re-certification: A targeted delay for devices already certified under the old directives to avoid a "new major bottleneck" before the 2028 transitional deadlines. Fast-Track Pathways: The establishment of an accelerated, 120-day pathway for breakthrough, orphan, and paediatric devices in areas of unmet medical need. 2. Product and Market Expansion Despite the regulatory backdrop, companies continue to secure funding and expand their commercial presence: Cardiology Device Rollout: Elixir Medical began its full European commercial rollout of its LithiX Intravascular Lithotripsy (IVL) device following its CE mark. This indicates a significant market entry for a new technology designed to treat calcified coronary arteries. Remote Patient Monitoring (RPM) Funding: RDS (France) secured a €14 million Series A funding round. The capital is aimed at industrializing and expanding the rollout of its MultiSense RDS, a CE-marked connected patch for continuous remote patient monitoring across Europe, highlighting strong investor interest in connected health hardware. 3. AI and Robotics Investment Hubs Investment into advanced MedTech infrastructure remains high: Medtronic's Robotics Hub: Medtronic plc announced plans to double its London presence to create a global hub for surgical robotics and AI. This action underscores the long-term strategic commitment of major global MedTech players to anchor their advanced technology development within Europe, leveraging the region's talent pool. AI for Adjacent Sectors: Lupa (UK) secured a €17 million Series A to scale its AI-native operating system for veterinary clinics and launch a dedicated Veterinary AI Lab in Europe, demonstrating the spread of MedTech innovation models into parallel healthcare sectors.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

This Week in European MedTech - Week 2 October 2025

White Sticky Note With 2025 October Calendar And Red Push Pin On Blue Background

Major developments in European HealthTech this week centred on a landmark AI regulatory approval, strategic international partnerships, and continued focus on regulatory reform. Here are the key highlights:1. Landmark AI Regulatory Approval Autonomous AI Care: A significant regulatory breakthrough was reported as Flok Health's AI-powered physiotherapy clinic secured Class IIa Medical Device approval under EU regulations. Significance: This is a major milestone, reportedly making it the first time an AI system in the UK or Europe has been approved for fully autonomous, end-to-end care, including diagnostic and treatment decisions, without constant human supervision. Real-World Impact: Pilot data from one NHS trust showed the AI platform more than halved waiting lists for back pain. 2. Investment and Funding Activity Investment continues to flow, particularly into AI-driven solutions: Simple Life (UK): Secured a $35 million Series B funding round to scale its AI health coach platform, a major injection of capital into the consumer wellness space. Early-Stage AI Scribes: There was notable funding for startups in the AI-powered administrative sector, mirroring the broader trend of automating clinical workflows:praxipal (Germany): Raised $6.7 million in seed funding for its AI workforce aimed at German healthcare front desks. Vocca (Voice AI): Raised $5.5 million in seed funding to bring AI phone assistants to the healthcare sector. Drug Discovery: DaltonTx (UK) completed a £4 million seed round to advance its intelligence backbone for drug discovery, underscoring the ongoing investor appetite for TechBio. 3. Pressure on Regulatory Reform Call for Harmonisation: MedTech Europe submitted its recommendations for the forthcoming European Innovation Act, calling for urgent and fundamental reforms to the EU's medical device regulations (MDR and IVDR). Key Complaint: The industry group claims the existing regulations have "structural problems," leading to administrative burden, complexity, and fragmentation that is "eroding Europe's attractiveness for innovation and delaying patient access." Proposed Fix: MedTech Europe is pushing for a more centralized governance structure and a streamlined pathway from research to market for life science innovations. 4. UK Clinical Trial Acceleration MHRA Approval Times: The UK's Medicines and Healthcare products Regulatory Agency (MHRA)announced that its recent reforms have more than halved the time it takes to approve clinical trials, falling from 91 days to 41 days, a positive sign for biotech and medical device companies conducting research in the UK.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

This Week in European HealthTech - Week 2 October 2025

Ambient Voice Technology (AVT), or AI scribes, holds significant potential to reduce the administrative burden on NHS staff, but its adoption faces several complex challenges across regulatory, clinical, and ethical domains.&nbsp;The main challenges in the NHS surrounding the use of AVT include:1. Regulatory and Governance Challenges A primary concern is the proper regulation and assurance of these tools, particularly as many suppliers initially failed to meet NHS standards:Medical Device Classification: AVT solutions that generate summaries of consultations (rather than just simple transcription) are typically classified as medical devices and must be registered with the Medicines and Healthcare products Regulatory Agency (MHRA), usually as a minimum of a Class I medical device.Compliance and Unregistered Tools: NHS England has issued warnings for staff to stop using unregistered AI scribe tools that do not meet essential assurance standards, posing risks to patient safety and data protection.Safety Standards: NHS organisations must ensure compliance with rigorous safety standards like DCB0129 and DCB0160 (Digital Clinical Risk Management), and complete a comprehensive Data Protection Impact Assessment (DPIA) before deployment.Supplier Compliance: Many vendors approaching the NHS have not complied with basic governance standards, such as providing MHRA clinical safety and technical/cyber platform assurance.2. Clinical and Safety Risks Even with compliant tools, the nature of the technology and its use in a clinical setting introduces new risks:Accuracy and AI Errors: AI models, especially those using Generative AI, can introduce errors, inaccuracies, or even "hallucinations" (generating false or misleading clinical information).Omission of Nuance: AVT can struggle with the nuances of human communication, such as sarcasm, significant silences, or subtext, particularly in fields like mental health, which can lead to clinically "vacuous" notes&nbsp; Over-reliance and "Editing Fatigue": Clinicians face the risk of becoming overly reliant on the AI's output (automation bias). Furthermore, correcting lengthy, well-written but clinically inaccurate notes can sometimes be more draining than writing them from scratch, leading to "editing fatigue."&nbsp; &nbsp; Inconsistent Data Capture: Challenges remain with the technology's performance in varied real-world conditions, such as noisy clinical settings, different accents, and when multiple speakers are present.3. Data Privacy and Consent ConcernsHandling highly sensitive patient conversations requires strict adherence to privacy legislation:Informed Consent: Patients must be transparently informed that AVT is being used, why, and how their data will be processed, stored, and shared. Consent must be explicit and informed, not just a 'tick-box,' and patients must be offered an alternative or the right to stop the recording.Biometric Data and Re-identification: Voice recordings are considered biometric data and are difficult to fully anonymise, as accent, pitch, and content can still lead to re-identification, raising significant data protection risks under UK GDPR.Data Processing and Storage: There are major concerns over where confidential patient data is transferred, how long it is retained, and whether vendors might reuse identifiable data for training their AI models without an appropriate legal basis.Cybersecurity: Organisations must ensure robust cybersecurity controls, including compliance with the Data Security and Protection Toolkit (DSPT), to protect sensitive recordings and transcripts.4. Integration and Adoption Barriers &nbsp; The practical implementation of AVT across the vast NHS presents organisational and technical hurdles:Interoperability: Seamless integration with existing electronic patient records (EPRs), such as EMIS and SystmOne, remains a significant challenge. Without full integration, clinicians are still left with the administrative task of copying and pasting, reducing the technology's benefit.ragmented Procurement: Procurement processes can be fragmented across different NHS trusts and Integrated Care Boards (ICBs), which can impede standardised, equitable, and widespread adoption.Lack of Evidence and Capability: There is a call for further robust evidence of AVT's long-term impact on clinical workflows and patient outcomes. Additionally, NHS organisations need to build internal capability to assess and continually monitor these evolving tools.Impact on Patient-Clinician Trust: The presence of a "listening" non-human "third party" in the room can risk eroding the delicate relationship of trust and psychological safety between a patient and their clinician, especially for vulnerable patients (e.g., those with paranoia or a history of trauma).To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title=" lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk﻿</a>

Ambient Voice Technology challenges in the NHS

London Stock Exchange, The Royal Exchange Bank, Royal Exchange Building and Duke of Wellington Statue in the Financial City of London, Cornhill street and Threadneedle street, british double decker bus

The Bank of England's warning of a potential AI tech bubble and a "sharp market correction" carries significant implications for the HealthTech and Healthcare sectors, which have seen a massive influx of investment driven by AI optimism.Impact on HealthTech Valuations and InvestmentThe primary concern raised by the Bank of England's Financial Policy Committee (FPC) is that equity valuations, particularly for AI-focused companies, appear "stretched" and may be driven more by hype than proven returns. For HealthTech, this risk is particularly acute:Valuation Correction: If the overall AI bubble bursts, HealthTech companies relying heavily on the "AI" label and projected, rather than realized, future earnings are highly vulnerable to a sharp drop in valuation. Early-stage AI-focused startups have been commanding premium valuations (2–5x higher multiples) than their non-AI counterparts, a sign of speculative fervor that a market correction would likely eliminate.Funding Crunch: A sudden market correction could cause finance to dry up for households and businesses, including vital funding for startups. HealthTech companies, especially at the Series A and B stages, which were already facing challenges in securing follow-on funding, would likely face an intensified "funding crunch."Disappointment Over Returns: The FPC noted that investors could be "disappointed by the progress or adoption of AI technology." This echoes external reports, including an MIT study, which found that a high percentage of organizations are seeing zero measurable return from their generative AI investments. In HealthTech, this is exemplified by cases like the US healthcare startup Forward Health, which closed abruptly after struggling to sustain revenue, highlighting the gap between AI hype and real-world profitability in a patient-service-focused environment. HealthTech-Specific Challenges Amplifying Risk The nature of the healthcare sector adds unique risks to the AI bubble dynamic:Hype vs. Reality in Care: The HealthTech sector is prone to "technosolutionism," the belief that technology alone can fix complex problems. However, industry analysis highlights that patients demand reassurance, empathy, and trust, not just automation. Startups that have pushed AI solutions without a clear path to adoption, or that have "overestimated both technology's ability and society's appetite to replace the human side of healthcare," are the most exposed. Safety and Regulation Bottlenecks: AI development in healthcare is inherently safety-critical, with significant focus on avoiding patient harm. Warnings from organizations like the World Health Organization (WHO) call for rigorous oversight. The long procurement cycles and the necessity for robust regulatory approval and data security in healthcare could act as "material bottlenecks to AI progress," a risk factor explicitly mentioned by the Bank of England's FPC. Concentration Risk in Adoption: While the UK's NHS is actively pursuing AI initiatives, such as a world-first AI safety warning system, the overall adoption of AI tools is often limited to a few leading providers. A lack of clear strategy to scale up AI tools could exacerbate inequalities in provision and access, meaning the broad, transformative impact expected by investors may be slower to materialize than in less regulated industries. Preparing for a Correction A market correction is viewed by some analysts not as the end of AI, but as a necessary correction that can clear the market of unproven, hype-driven companies, leaving behind more robust, legitimate suppliers with proven business models. For healthcare organizations utilizing HealthTech, the risk is operational continuity. They must:Assess Financial Stability of vendors, not just their technology. Scrutinise Sustainability by demanding credible, long-term operational plans. Build Continuity Safeguards into contracts to mitigate the risk of a supplier collapse.To discuss how Nelson Advisors can help your Health AI company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Bank of England sounds alarm over AI Tech Bubble: Impact on HealthTech Valuations and Investments

10 Key Factors for HealthTech and MedTech founders to consider in today's M&amp;A market environmentThe top 10 key factors for HealthTech and MedTech founders to consider in today's M&amp;A market, focusing on value drivers and due diligence preparation, are:1. Proprietary AI and Innovation 🤖Companies with proven, proprietary AI/ML algorithms, especially in areas like diagnostics, predictive analytics, and surgical robotics, are seeing premium valuations (e.g., 6-8x revenue). Buyers are actively seeking these cutting-edge technologies. Founder Focus: Clearly document and protect your unique AI/tech "moat." Be ready to demonstrate measurable outcomes and efficiency gains it provides.2. Regulatory Compliance and Data Privacy 🔒Due diligence is highly focused on regulatory risk. Any deficiencies in adherence to laws like HIPAA, GDPR,Stark Law, or in your formal Quality Management System (QMS) can severely reduce valuation or kill a deal. Founder Focus: Ensure meticulous documentation and a flawless track record of compliance. Clearly define and prove your data security and privacy protocols.3. Strong and Predictable Financial Metrics 📈Buyers prioritise financial health. Key drivers are sustainable revenue growth, high gross margins, and a significant percentage of recurring revenue (e.g., SaaS or subscription models). Founder Focus: Clean up your financials. Shift toward recurring revenue models and demonstrate a clear path to profitability or strong unit economics.4. Demonstrable Clinical and Commercial Validation 🔬Unlike general tech, healthtech/medtech value is tied to real-world efficacy. Buyers require robust, documented clinical studies and clear Return on Investment (ROI) for providers and payers. Founder Focus: Invest in generating high-quality clinical evidence. Document case studies that prove your product's impact on patient outcomes and cost savings.5. Clear Intellectual Property (IP) Ownership 🛡️Your IP is your core asset. Gaps in ownership—such as lack of "work for hire" agreements with contractors or missing employee IP assignment clauses—will be a major red flag during due diligence. Founder Focus: Conduct an internal IP audit. Ensure all patents, trademarks, and code ownership are legally clear, assigned to the company, and fully defensible.6. Alignment with Value-Based Care (VBC) 🤝Healthcare is shifting from fee-for-service to VBC. Companies that enable this transition (e.g., remote patient monitoring, population health, chronic disease management) are strategically valuable to payers and providers. Founder Focus: Frame your solution in terms of how it reduces costs and improves patient outcomes, directly supporting a VBC model.7. Scalable Processes and Management Team Depth 👥Buyers assess "key person risk." Over-reliance on the founder for key client relationships or daily operations raises concerns about post-acquisition sustainability. Founder Focus: Build a strong second-tier management team and document repeatable Standard Operating Procedures (SOPs). Prove the company can run and scale without the founders' constant involvement.8. Interoperability and Data Monetization Strategy 🔗The ability to seamlessly integrate with Electronic Health Records (EHRs) and other systems (interoperability) is crucial. Companies with clean, actionable data that can be ethically leveraged (monetization) command higher multiples. Founder Focus: Prioritize API development and integration capabilities. Demonstrate a clear, compliant strategy for how your data creates additional value.9. Customer Concentration and Acquisition Costs (CAC) 🎯High customer concentration (revenue dependent on one or two clients) signals a major risk to a buyer. Low Customer Acquisition Costs (CACs) are a key profitability driver. Founder Focus: Diversify your customer base to reduce concentration risk. Optimize your sales and marketing process to prove an efficient, scalable, and low CAC model.10. Understanding Alternative Deal Structures 💰To bridge valuation gaps between buyers and sellers, alternative structures are becoming common. These include earn-outs (additional payments based on future performance) and royalty/licensing agreements. Founder Focus: Be prepared to negotiate a portion of your deal value into an earn-out structure, especially if a buyer is cautious about future revenue projections. This shows confidence in your team and product's future performance.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

10 Key Factors for HealthTech and MedTech founders to consider in today's M&A market environment

October 2025 - small spiral desktop calendar, time and business concept

The major stories in the world of European MedTech this week are dominated by regulatory activity under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), a significant European Commission "Call for Evidence" for future reforms, and fresh funding for companies focused on connected and remote monitoring devices.Here are the top stories:1. Regulatory Pressure and Calls for MDR/IVDR Reform The central theme this week is the ongoing industry push for revisions and accommodations within the European Union's medical device regulations (MDR/IVDR):EU Call for Evidence for MDR/IVDR Future: The European Commission launched a "Call for Evidence" on the future of the MDR/IVDR, specifically a targeted revision aimed at reducing administrative burden, improving predictability, and enabling digitalisation. The deadline for industry feedback is October 6, 2025, making this the most time-sensitive policy story this week. MedTech Europe's Push for Immediate Action: The industry body, MedTech Europe, continued to press the EU for immediate regulatory changes by early 2026. Their requests include:A targeted postponement of re-certification requirements for devices already certified under the existing regulations to avoid a "new major bottleneck" before the 2028 deadline. The creation of a single, accountable governance structure to oversee the network of Notified Bodies (NBs), aiming to ensure a more efficient and globally competitive CE-marking system. The launch of planned pilots for expedited regulatory pathways for orphan, pediatric, and breakthrough devices. Regulatory Milestones: The industry saw updates on several detailed compliance issues:Confirmation of the Master UDI-DI (Unique Device Identification) implementation date for contact lenses being postponed to November 9, 2026. Publication of new guidance on addressing incomplete Technical Files for IVDR submissions from Team-NB. Updates on the status of MDR/IVDR implementation and the gradual rollout of the EUDAMED database. 2. MedTech Product Rollout and Commercial Growth Cardiology Device Rollout: Elixir Medical began its full European rollout of the LithiX high-capacity Intravascular Lithotripsy (IVL) device following its CE mark, with over 400 patients already treated across 16 countries. This marks a significant market entry for a new cardiology technology. 3. Key MedTech Funding and Expansion Recent funding activity highlights strong investment interest in both digital and hardware-based medical solutions:Remote Monitoring Device Funding: RDS (France) raised a €14 million Series A round to industrialise and expand its MultiSense RDS, a CE-marked connected patch for continuous remote patient monitoring across Europe. AI for Veterinary MedTech: Lupa (UK) secured a €17 Million Series A to scale its AI-native operating system for veterinary clinics and launch a dedicated Veterinary AI Lab in Europe, demonstrating the spread of MedTech innovation into adjacent healthcare sectors. Big Tech Investment in Surgical Robotics: Medtronic plc announced it is doubling its London presence to create a global hub for surgical robotics and AI, aligning with the ambitions of the NHS 10-Year Health Plan. 4. Broader Context and Industry Movement Staffing and Leadership: Dentsply Sirona appointed a new EVP &amp; Chief Commercial Officer to align its global business units with commercial execution, with the new executive bringing extensive experience from J&amp;J MedTech. Global Trade Impact: European medtech firms are closely watching the potential impact of a US Section 232 investigation and its potential to introduce tariffs, particularly monitoring whether it could override the Nairobi Protocol, which bans tariffs on products for people with disabilities.To discuss how Nelson Advisors can help your HealthTech or MedTech company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

This Week in European MedTech - Week 2 October 2025

This Week in European HealthTech - Week 2 October 2025

Ambient Voice Technology challenges in the NHS

Bank of England sounds alarm over AI Tech Bubble: Impact ...

10 Key Factors for HealthTech and MedTech founders to con...

This Week in European MedTech - Week 1 October 2025